Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~-Participants with Masseter Muscle Hypertrophy~Exclusion Criteria:~* Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function~* Prior botulinum toxin treatment of any serotype to the masseter muscle or lower face~* History of dental or surgical procedure for lower facial shaping or masseter muscle reduction~* History of or current temporomandibular joint disorder (TMJD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® 24U (Type: ACTIVE_COMPARATOR): Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
- BOTOX® 48U (Type: ACTIVE_COMPARATOR): Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
- BOTOX® 72U (Type: ACTIVE_COMPARATOR): Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
- BOTOX® 96U (Type: ACTIVE_COMPARATOR): Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Based on this trial design, predict the completion outcome and termination type (if applicable).